13F Holdings
中文EN

PROK PROKIDNEY CORP.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850270 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.2%
TTM net income YoY-45.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-24,830.3%
Net margin-13,326.7%
FCF margin-21,655.0%
EBITDA margin-24,002.1%

Returns

ROE—
ROA-36.8%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets15.8%
Debt / equity—
Current ratio5.04x
Interest coverage-10,690.83x

Cash quality & payout

Operating cash flow / net income1.48x
Accruals ratio17.8%
Payout ratio—
Capex / revenue1,884.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY20212021-12-31
Income statement
Revenue$893,000$76,000$0$0—
R&D expense$114.12M$127.67M$106.71M$82.07M$46.26M
SG&A expense$51.78M$56.08M$44.81M$70.94M$8.86M
Operating income-$165.01M-$183.68M-$151.52M-$153.01M-$55.11M
Interest expense$4,000$9,000$12,000$215,000$0
Pretax income-$151.20M-$163.93M-$129.45M-$147.24M-$55.11M
Income tax$414,000-$598,000$6.00M$896,000$38,000
Net income-$68.99M-$61.19M-$35.47M-$148.13M-$55.15M
EBITDA-$158.43M-$178.24M-$147.67M-$149.97M-$53.13M
EPS (basic)———-0.23—
EPS (diluted)———-0.23—
Weighted avg. shares (diluted)———61.54M—
Balance sheet
Cash & equivalents$108.54M$99.12M$60.65M$490.25M$20.56M
Current assets$280.68M$395.88M$374.15M$504.72M$27.27M
PP&E, net$51.23M$42.22M$42.14M$10.71M$11.36M
Intangibles——$0$213,000$428,000
Total assets$335.57M$441.07M$420.55M$518.00M$40.30M
Current liabilities$30.74M$36.22M$25.04M$10.87M$12.31M
Total liabilities$34.78M$39.44M$29.22M$13.06M$13.38M
Shareholders' equity-$1.01B-$994.95M-$1.10B-$1.10B$26.92M
Cash flow statement
Operating cash flow-$120.12M-$126.35M-$90.07M-$77.09M-$50.30M
Capital expenditure$15.20M$29.51M$34.20M$1.85M$5.19M
Free cash flow-$135.31M-$155.86M-$124.27M-$78.94M-$55.49M
Investing cash flow$103.97M$20.41M-$329.98M-$1.74M-$5.19M
Financing cash flow$25.57M$144.41M-$9.55M$548.52M$71.47M
Depreciation & amortization$6.58M$5.43M$3.85M$3.04M$1.98M
Stock-based compensation$25.34M$29.37M$30.85M$74.47M$699,000
Share buybacks$0$0$9.50M$0$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.